<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02211482</url>
  </required_header>
  <id_info>
    <org_study_id>FH-18</org_study_id>
    <nct_id>NCT02211482</nct_id>
  </id_info>
  <brief_title>Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study</brief_title>
  <acronym>PADDLE</acronym>
  <official_title>Dolutegravir-Lamivudine as Dual Therapy in Naive HIV-Infected Patients: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Huésped</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundación Huésped</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the antiviral efficacy, safety and tolerability of&#xD;
      dual therapy with 3TC and DTG as initial therapy among naïve HIV patients&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the antiviral efficacy, safety and tolerability of&#xD;
      dual therapy with 3TC and DTG as initial therapy among naïve HIV patients.&#xD;
&#xD;
      Data collected in this study would inform the development of larger studies designed to&#xD;
      evaluate metabolic and long term safety, impact on inflammatory biomarkers, efficacy, safety&#xD;
      and cost effectiveness of this strategy among naïve and suppressed patients.&#xD;
&#xD;
      Primary endpoint:Proportion of patients with HIV-1 RNA levels of less than 50 copies/mL at&#xD;
      week 48.&#xD;
&#xD;
      Secondary endpoints: Frequency, type and severity of adverse events and laboratory&#xD;
      abnormalities, Proportion of patients with HIV-1 RNA &lt;1000 copies/mL at week 12, Proportion&#xD;
      of patients with HIV-RNA &lt;400 at week 24 Number and type of resistance mutations in case of&#xD;
      virologic failure (defined as a confirmed viral above 400 copies/mL after week 24 copies/mL&#xD;
      or viral rebound at any timepoint) Changes in CD4+ lymphocyte count between baseline and 48&#xD;
      weeks, Estimation of the viral decay compared to historical data.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">April 2017</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Efficacy Outcome Measure</measure>
    <time_frame>48 weeks</time_frame>
    <description>Percentage of Participants with HIV-1 RNA levels of less than 50 copies/mL at week 48 by ITT analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety</measure>
    <time_frame>48 week</time_frame>
    <description>Frequency, type and severity of adverse events and laboratory abnormalities</description>
  </secondary_outcome>
  <other_outcome>
    <measure>efficacy</measure>
    <time_frame>24 weeks</time_frame>
    <description>Proportion of patients with HIV-RNA &lt;400 at week 24</description>
  </other_outcome>
  <other_outcome>
    <measure>safety</measure>
    <time_frame>48 weeks</time_frame>
    <description>change in lipid profile between baseline and week 48.</description>
  </other_outcome>
  <other_outcome>
    <measure>efficacy</measure>
    <time_frame>12 weeks</time_frame>
    <description>Proportion of patients with HIV-1 RNA &lt;1000 copies/mL at week 12</description>
  </other_outcome>
  <other_outcome>
    <measure>Number and type of resistance mutations in case of virologic failure (defined as a confirmed viral above 400 copies/mL after week 24 copies/mL or viral rebound at any timepoint)</measure>
    <time_frame>48 weeks</time_frame>
    <description>Number and type of resistance mutations in case of virologic failure (defined as a confirmed viral above 400 copies/mL after week 24 copies/mL or viral rebound at any timepoint)</description>
  </other_outcome>
  <other_outcome>
    <measure>efficacy</measure>
    <time_frame>48 weeks</time_frame>
    <description>Changes in CD4+ lymphocyte count between baseline and 48 weeks</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>HIV-1 Infection</condition>
  <arm_group>
    <arm_group_label>Dolutegravir , lamivudine</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Dolutegravir 50 mg QD plus lamivudine 300 mg QD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dolutegravir, lamivudine</intervention_name>
    <description>single arm</description>
    <arm_group_label>Dolutegravir , lamivudine</arm_group_label>
    <other_name>dolutegravir</other_name>
    <other_name>lamivudine</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. &gt; 18 years of age&#xD;
&#xD;
          2. Documented HIV-1 infection (positive ELISA plus a confirmatory Western Blot; or plasma&#xD;
             HIV-1 RNA ≥10,000 copies/mL)&#xD;
&#xD;
          3. Voluntarily signed and dated , IRB / IEC approved informed consent form&#xD;
&#xD;
          4. Agrees not to take any other medication during the study&#xD;
&#xD;
          5. Screening HIV RNA &gt;5,000 copies/mL and ≤ 100,000 copies/ml&#xD;
&#xD;
          6. Naïve to ARV therapies&#xD;
&#xD;
          7. CD4 ≥200 cells/mL&#xD;
&#xD;
          8. Subjects can comply with protocol requirements&#xD;
&#xD;
          9. Subject's general medical condition, in the investigator's opinion, does not interfere&#xD;
             with assessments and completion of the trial&#xD;
&#xD;
         10. Patient is a male or a female not breastfeeding or pregnant&#xD;
&#xD;
         11. A female, may be eligible if she:&#xD;
&#xD;
               1. is of non-child-bearing potential&#xD;
&#xD;
               2. is of child-bearing potential with a negative pregnancy test at Screening and Day&#xD;
                  1 and agrees to use one of the following methods:&#xD;
&#xD;
                    -  Complete abstinence from penile-vaginal intercourse from 2 weeks prior to&#xD;
                       administration of IP, throughout the study, and for at least 2 weeks after&#xD;
&#xD;
                    -  Double barrier method (male condom/spermicide, male condom/diaphragm,&#xD;
                       diaphragm/spermicide)&#xD;
&#xD;
                    -  IUD and male condom&#xD;
&#xD;
                    -  Male partner sterilization confirmed and male condom&#xD;
&#xD;
                    -  Approved hormonal contraception and male condom&#xD;
&#xD;
                    -  Any other method with published data showing that the expected failure rate&#xD;
                       is &lt;1% per year and use male condom&#xD;
&#xD;
                    -  Any contraception method must be used for at least 2 weeks after&#xD;
                       discontinuation of IP&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        1. Genotypic resistance to lamivudine at screening,as per IAS -USA Panel 2013 2. Alcohol or&#xD;
        drug use that might impact on adherence 3. Subjects positive for Hepatitis B at screening&#xD;
        (+HBsAg), or anticipated need for Hepatitis C virus (HCV) therapy during the study 4.&#xD;
        Lactating, pregnancy or fertile women willing to be pregnant 5. Concomitant use of lowering&#xD;
        lipid drugs, interferon, interleukin-2, cytotoxic chemotherapy, Dofetilide (or pilsicainide&#xD;
        ) or immunosuppressors at study entry 6. Grade 4 lab abnormalities 7. Primary HIV infection&#xD;
        (indeterminate WB or previous negative HIV in the last 6 months.) 8. Opportunistic&#xD;
        infection (CDC C category) or other disease and/or clinical condition that, in the&#xD;
        investigator's opinion, would compromise the patient's safety or outcome of the study;&#xD;
        including malignancy other than cutaneous Kaposi's sarcoma, basal cell carcinoma, or&#xD;
        resected, non-invasive cutaneous squamous cell carcinoma, or cervical intraepithelial&#xD;
        neoplasia 9. Subjects who in the investigator's judgment, poses a significant suicidality&#xD;
        risk 10. History or presence of allergy to the study drugs or their components or drugs of&#xD;
        their class 11. Treatment with any of the following agents within 28 days of Screening:&#xD;
        radiation therapy; cytotoxic chemotherapeutic agents; any immunomodulators that alter&#xD;
        immune responses or treatment with an HIV-1 immunotherapeutic vaccine within 90 days of&#xD;
        Screening or exposure to an experimental drug or experimental vaccine within either 28&#xD;
        days, 5 half-lives of the test agent, or twice the duration of the biological effect of the&#xD;
        test agent, whichever is longer, prior to the first dose of investigational product 12. Any&#xD;
        acute laboratory abnormality at Screening, which, in the opinion of the Investigator, would&#xD;
        preclude the subject's participation in the study of an investigational compound 13.&#xD;
        Alanine aminotransferase (ALT) &gt;5 times the upper limit of normal (ULN), or ALT ≥ 3xULN and&#xD;
        bilirubin ≥ 1.5xULN (with &gt;35% direct bilirubin) 14. Creatinine clearance of &lt;50 mL/min via&#xD;
        Cockcroft-Gault method 15. Subjects with moderate to severe hepatic impairment (Class B or&#xD;
        greater) as determined by Child-Pugh classification&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pedro Cahn, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundacion Huesped</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundacion Huesped</name>
      <address>
        <city>Caba</city>
        <state>Buenos Aires</state>
        <zip>C1202ABB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
  </location_countries>
  <verification_date>August 2017</verification_date>
  <study_first_submitted>August 5, 2014</study_first_submitted>
  <study_first_submitted_qc>August 6, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2014</study_first_posted>
  <last_update_submitted>August 10, 2017</last_update_submitted>
  <last_update_submitted_qc>August 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 14, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fundación Huésped</investigator_affiliation>
    <investigator_full_name>Pedro Cahn</investigator_full_name>
    <investigator_title>PhD</investigator_title>
  </responsible_party>
  <keyword>HIV-1 infected patients</keyword>
  <keyword>dual therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lamivudine</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>to publish week 48 study results</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

